Dr. Christopher Lucci, MD
NPI: 1447241955
Total Payments
$966,867
2024 Payments
$131,813
Companies
34
Transactions
1,267
Medicare Patients
1,037
Medicare Billing
$168,073
Payment Breakdown by Category
Other$746,718 (77.2%)
Travel$168,464 (17.4%)
Consulting$28,499 (2.9%)
Food & Beverage$23,084 (2.4%)
Education$102.86 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $723,394 | 331 | 74.8% |
| Travel and Lodging | $168,464 | 355 | 17.4% |
| Consulting Fee | $28,499 | 16 | 2.9% |
| Honoraria | $23,324 | 7 | 2.4% |
| Food and Beverage | $23,084 | 550 | 2.4% |
| Education | $102.86 | 8 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $453,325 | 478 | $0 (2024) |
| Corcept Therapeutics | $220,123 | 233 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $171,230 | 232 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $104,968 | 121 | $0 (2024) |
| Esperion Therapeutics, Inc. | $9,103 | 18 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $4,210 | 15 | $0 (2019) |
| Mannkind Corporation | $781.99 | 30 | $0 (2024) |
| Lilly USA, LLC | $386.25 | 19 | $0 (2024) |
| ARBOR PHARMACEUTICALS, INC. | $312.20 | 22 | $0 (2021) |
| Bayer Healthcare Pharmaceuticals Inc. | $302.23 | 19 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $131,813 | 161 | Corcept Therapeutics ($106,989) |
| 2023 | $110,180 | 146 | Corcept Therapeutics ($44,753) |
| 2022 | $165,897 | 194 | Novo Nordisk Inc ($75,281) |
| 2021 | $106,762 | 137 | Novo Nordisk Inc ($77,815) |
| 2020 | $82,925 | 126 | Novo Nordisk Inc ($69,642) |
| 2019 | $121,734 | 152 | Novo Nordisk Inc ($82,228) |
| 2018 | $144,077 | 209 | Novo Nordisk Inc ($85,407) |
| 2017 | $103,478 | 142 | AstraZeneca Pharmaceuticals LP ($57,800) |
All Payment Transactions
1,267 individual payment records from CMS Open Payments — Page 1 of 51
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $20.26 | General |
| Category: Cardio-renal | ||||||
| 12/11/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $3.28 | General |
| Category: Endocrinology | ||||||
| 12/05/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $34.11 | General |
| Category: Endocrinology | ||||||
| 11/14/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,906.25 | General |
| 11/14/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $121.39 | General |
| 11/14/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $45.56 | General |
| 11/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: Cardio-renal | ||||||
| 11/12/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: DIABETES MEDICINE | ||||||
| 11/06/2024 | RECORDATI_RARE_DISEASES_INC. | SIGNIFOR LAR (Drug), ISTURISA | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: ENDOCRINE AGENT | ||||||
| 11/05/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $116.37 | General |
| Category: DIABETES MEDICINE | ||||||
| 10/30/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.39 | General |
| Category: Cardio-renal | ||||||
| 10/23/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $22.58 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 10/22/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| Category: Diabetes | ||||||
| 10/17/2024 | Corcept Therapeutics | Korlym (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,900.00 | General |
| Category: Endocrinology | ||||||
| 10/17/2024 | Corcept Therapeutics | Korlym (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,400.00 | General |
| Category: Endocrinology | ||||||
| 10/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $22.91 | General |
| Category: Cardio-renal | ||||||
| 10/15/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $26.96 | General |
| Category: Endocrinology | ||||||
| 10/10/2024 | Corcept Therapeutics | Korlym (Drug) | Honoraria | Cash or cash equivalent | $9,960.00 | General |
| Category: Endocrinology | ||||||
| 10/10/2024 | Corcept Therapeutics | Korlym (Drug) | Travel and Lodging | In-kind items and services | $887.95 | General |
| Category: Endocrinology | ||||||
| 10/10/2024 | Corcept Therapeutics | Korlym (Drug) | Travel and Lodging | In-kind items and services | $667.94 | General |
| Category: Endocrinology | ||||||
| 10/10/2024 | Corcept Therapeutics | Korlym (Drug) | Travel and Lodging | Cash or cash equivalent | $270.68 | General |
| Category: Endocrinology | ||||||
| 10/10/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $173.79 | General |
| Category: Endocrinology | ||||||
| 10/10/2024 | Corcept Therapeutics | Korlym (Drug) | Travel and Lodging | Cash or cash equivalent | $88.49 | General |
| Category: Endocrinology | ||||||
| 10/10/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $69.52 | General |
| Category: Endocrinology | ||||||
| 10/10/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $69.52 | General |
| Category: Endocrinology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 279 | 599 | $98,297 | $49,740 |
| 2022 | 6 | 217 | 446 | $76,797 | $36,704 |
| 2021 | 7 | 244 | 488 | $70,677 | $39,138 |
| 2020 | 9 | 297 | 633 | $88,081 | $42,490 |
Total Patients
1,037
Total Services
2,166
Medicare Billing
$168,073
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 106 | 355 | $53,250 | $30,430 | 57.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 47 | 47 | $8,225 | $5,808 | 70.6% |
| 93241 | Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 17 | 19 | $17,100 | $3,670 | 21.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 45 | 63 | $6,615 | $3,447 | 52.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 19 | $3,325 | $2,461 | 74.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $2,925 | $1,524 | 52.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 18 | 57 | $4,959 | $1,376 | 27.8% |
| 99487 | Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 11 | 12 | $1,128 | $884.40 | 78.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 11 | 14 | $770.00 | $140.01 | 18.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 87 | 254 | $38,100 | $21,914 | 57.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 49 | 49 | $8,575 | $6,186 | 72.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 43 | 84 | $8,820 | $4,539 | 51.5% |
| 93241 | Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2022 | 11 | 12 | $10,800 | $2,107 | 19.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 11 | 11 | $7,370 | $1,014 | 13.8% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 16 | 36 | $3,132 | $944.15 | 30.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 75 | 219 | $32,850 | $18,793 | 57.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 51 | 51 | $8,925 | $6,577 | 73.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 52 | 102 | $10,710 | $5,911 | 55.2% |
| 99487 | Complex chronic care management services, first 60 minutes clinical staff time per calendar month | Office | 2021 | 33 | 65 | $6,110 | $4,228 | 69.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 11 | 14 | $2,450 | $1,820 | 74.3% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2021 | 11 | 11 | $7,370 | $1,089 | 14.8% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 11 | 26 | $2,262 | $719.16 | 31.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 83 | 249 | $37,350 | $19,542 | 52.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 65 | 139 | $14,595 | $6,148 | 42.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 43 | 43 | $7,525 | $4,839 | 64.3% |
About Dr. Christopher Lucci, MD
Dr. Christopher Lucci, MD is a Public Health & General Preventive Medicine healthcare provider based in Rockport, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/03/2005. The National Provider Identifier (NPI) number assigned to this provider is 1447241955.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Lucci, MD has received a total of $966,867 in payments from pharmaceutical and medical device companies, with $131,813 received in 2024. These payments were reported across 1,267 transactions from 34 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($723,394).
As a Medicare-enrolled provider, Lucci has provided services to 1,037 Medicare beneficiaries, totaling 2,166 services with total Medicare billing of $168,073. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Public Health & General Preventive Medicine
- Location Rockport, TX
- Active Since 11/03/2005
- Last Updated 04/24/2015
- Taxonomy Code 2083P0901X
- Entity Type Individual
- NPI Number 1447241955
Products in Payments
- Ozempic (Drug) $229,872
- Korlym (Drug) $220,123
- XARELTO (Drug) $90,742
- RYBELSUS (Drug) $90,477
- INVOKANA (Drug) $80,483
- FARXIGA (Drug) $64,088
- Rybelsus (Drug) $53,210
- Tresiba (Drug) $42,130
- BYDUREON (Drug) $40,866
- NEXLIZET (Drug) $9,010
- TOUJEO (Drug) $1,955
- NO PRODUCT DISCUSSED (Drug) $1,890
- AFREZZA (Drug) $781.99
- Kerendia (Drug) $302.23
- RECORLEV (Drug) $223.26
- t:slim X2 Insulin Pump with Control-IQ (Device) $197.88
- Edarbi (Drug) $195.64
- TRULICITY (Drug) $192.55
- PRALUENT (Drug) $178.39
- SOLIQUA (Drug) $165.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.